Cyclic Deoxyribonucleotide Prodrugs for Liver Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 5-fluorouracil-based therapies face challenges with short biological half-life, narrow therapeutic index, and significant side effects due to inefficient liver targeting, necessitating the development of compounds that can selectively deliver pharmaceutical agents to the liver with enhanced efficacy and reduced toxicity.
Innovation Solution
Development of novel 5-fluorouracil derived cyclic deoxyribonucleotide compounds that are designed for oral delivery to the liver, utilizing liver-targeting mechanisms to enhance drug distribution and reduce side effects by acting as substrates for liver enzymes like CYP3A4, thereby improving therapeutic index and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 5-fluorouracil is used as a therapeutic agent, then cancer treatment efficacy is achieved, but biological half-life is very short and therapeutic index is narrow
Solution Approach 1:
The patent applies preliminary action by designing prodrug compounds (cyclic deoxyribonucleotide compounds) that are converted to active 5-fluorouracil in the liver before exerting therapeutic effect. This preliminary transformation allows the drug to be administered orally and activated selectively at the target site, thereby extending the effective duration of action while maintaining cancer treatment efficacy
Solution Approach 2:
The patent uses cyclic deoxyribonucleotide compounds as intermediary substances that serve as prodrugs. These intermediaries are converted by liver enzymes (CYP3A4) into active 5-fluorouracil, allowing extended circulation time and selective liver targeting, thus resolving the contradiction between short half-life and treatment efficacy
2Reliability
If 5-fluorouracil is administered systemically, then cancer cells are targeted, but side effects outside the liver increase
Solution Approach 1:
The patent applies local quality by designing compounds with selective liver targeting properties. The cyclic deoxyribonucleotide compounds are specifically activated by liver enzymes CYP3A4, creating a localized therapeutic effect in the liver while minimizing systemic exposure and side effects in other organs
Solution Approach 2:
The patent changes the chemical parameters of 5-fluorouracil by converting it into cyclic deoxyribonucleotide prodrugs with different pharmacokinetic properties. These modified compounds exhibit enhanced liver selectivity and reduced systemic toxicity, resolving the contradiction between effective cancer treatment and reduction of off-target side effects
3Reliability
If conventional 5-fluorouracil analogs are used, then some cancer types are treated, but drug delivery efficiency to the liver is insufficient
Solution Approach 1:
The patent introduces cyclic deoxyribonucleotide compounds as intermediary prodrugs that are specifically transported to and activated in the liver. This intermediary approach enhances liver delivery efficiency compared to conventional 5-fluorouracil analogs, while maintaining treatment coverage for various cancer types
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of 5-fluorouracil by creating cyclic deoxyribonucleotide derivatives with improved liver uptake characteristics. These parameter changes result in enhanced drug delivery efficiency to the liver while preserving the ability to treat multiple cancer types
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds achieve efficient liver targeting, prolonging drug half-life and enhancing absorption, leading to improved therapeutic outcomes for cancers such as hepatocellular carcinoma and other liver-related diseases while minimizing side effects outside the liver.
Implementation Method 1
utilizing liver-targeting mechanisms to enhance drug distribution and reduce side effects by acting as substrates for liver enzymes like CYP3A4
Data Source
AI summary
Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.